^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    medroxyprogesterone

    Company:
    Generic mfg.
    Drug class:
    Progesterone receptor agonist
    Related drugs:
    1m
    Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia (clinicaltrials.gov)
    P2, N=38, Recruiting, Peking University People's Hospital | Trial completion date: Feb 2025 --> Jun 2025
    Trial completion date
    |
    medroxyprogesterone • atorvastatin
    2ms
    A multicenter, randomized, double-blind, placebo-controlled, parallel-design phase III clinical study to evaluate the efficacy and safety of oral relugoli tablets in the treatment of heavy menstrual bleeding associated with uterine fibroids (ChiCTR2400088811)
    P3, N=120, Not yet recruiting, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    New P3 trial
    |
    medroxyprogesterone • estradiol valerate
    5ms
    Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer (clinicaltrials.gov)
    P=N/A, N=16, Not yet recruiting, Peking University People's Hospital
    New trial
    |
    medroxyprogesterone
    9ms
    Euploid Rate of Blastocyst Derived From PPOS VS Antagonist Protocol (clinicaltrials.gov)
    P=N/A, N=240, Completed, Shanghai First Maternity and Infant Hospital | Trial completion date: Jul 2023 --> Feb 2024
    Trial completion date
    |
    medroxyprogesterone • Cetrotide (cetrorelix)
    11ms
    RESToRE: Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer (clinicaltrials.gov)
    P4, N=250, Recruiting, University of British Columbia
    Trial completion date • Trial primary completion date
    |
    medroxyprogesterone
    1year
    Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia (clinicaltrials.gov)
    P2, N=38, Recruiting, Peking University People's Hospital
    New P2 trial
    |
    medroxyprogesterone
    1year
    Efficacy and prognosis of adjuvant treatment of endometrial cancer with medroxyprogesterone acetate COX regression analysis. (PubMed, World J Clin Cases)
    Age, pathological type, molecular typing, and myometrial infiltration were all relevant factors affecting the prognosis of early-stage high-risk endometrial cancer. The potential long-term prognostic benefit of adjuvant postoperative radiotherapy in patients with early-stage high-risk endometrial cancer is worthy of clinical consideration.
    Journal
    |
    medroxyprogesterone
    over1year
    RESToRE: Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer (clinicaltrials.gov)
    P4, N=250, Recruiting, University of British Columbia | Not yet recruiting --> Recruiting
    Enrollment open
    |
    medroxyprogesterone
    2years
    RAINBO: Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (clinicaltrials.gov)
    P2/3, N=1611, Recruiting, Leiden University Medical Center | Initiation date: Jun 2022 --> Nov 2021
    Trial initiation date
    |
    ER (Estrogen receptor) • POLE (DNA Polymerase Epsilon)
    |
    ER positive • MSI-H/dMMR • POLE mutation
    |
    Lynparza (olaparib) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • megestrol • medroxyprogesterone
    over2years
    RAINBO: Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (clinicaltrials.gov)
    P2/3, N=1611, Recruiting, Leiden University Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PGR (Progesterone receptor) • POLE (DNA Polymerase Epsilon)
    |
    MSI-H/dMMR • POLE mutation • PGR positive
    |
    Lynparza (olaparib) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • megestrol • medroxyprogesterone
    over2years
    RAINBO: Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (clinicaltrials.gov)
    P2/3, N=1611, Not yet recruiting, Leiden University Medical Center
    New P2/3 trial
    |
    PGR (Progesterone receptor) • POLE (DNA Polymerase Epsilon)
    |
    MSI-H/dMMR • POLE mutation • PGR positive
    |
    Lynparza (olaparib) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • megestrol • medroxyprogesterone